Focusing on the national strategic objectives, the laboratory focuses on the perinatal field of major pregnancy diseases and other issues to carry out in-depth research, explore the pathogenesis of diseases, while focusing on the exploration and application of cutting-edge technology, as well as multidisciplinary cooperation and exchange, and actively promote the transformation of scientific and technological achievements, accelerate the transformation of scientific and technological innovation, and provide effective solutions to solve the key problems in the field of maternal and fetal health. At present, the laboratory has 39 permanent researchers, including 3 experts from the Overseas High-level Talent Introduction Program, Vice Chairman of the Perinatal Medicine Branch of the Chinese Medical Association, national candidate of the Ten Million Talents Project, expert enjoying the State Council's Special Allowance, young and middle-aged expert with outstanding contribution to the National Health and Planning Commission (NHPC), member of the Expert Committee of the National Center of Obstetrics and Gynaecology Quality Control of the National Health and Planning Commission (NHPC), and second batch of Chongqing Chief Medical Expert, The first batch of Chongqing medical leaders, Bayu Scholars Distinguished Professor, Chair Professor, 2 Chongqing 10 million project leaders, 2 Chongqing academic and technical leaders, 2 young and middle-aged medical high-end reserve talents in Chongqing; Chongqing Excellence Program - young top talent 1. In addition, there are 9 full-time auxiliary staff members, and the laboratory has trained more than 200 doctoral and master's degree students and international students. Members of the laboratory team have received more than 40 national project grants (including the National Natural Science Foundation of China's key international cooperation projects and the National Key Research and Development Program), and have been responsible for a total of more than 50 million yuan in funding.
Positioning and Objectives
With the rapid development of China's society and economy as well as the change of the birth policy, the needs and expectations of the general public for maternal and child health have reached an unprecedented height. Maternal-fetal medicine is dedicated to the health of mothers and infants, the reduction of birth defects, and the service of the “three-child birth policy”. The construction of this laboratory aims to:
(1) Build a research platform for maternal-fetal medicine with international leading level;
(2) Incubate and produce a number of internationally advanced scientific research results with independent intellectual property rights, with a view to achieving major breakthroughs in certain areas of maternal-fetal medicine;
(3) Cultivate and nurture a group of highly qualified clinical and scientific research talents in maternal-fetal medicine with international competition awareness and capability.
Main Research Platforms
The Chongqing Key Laboratory of Maternal-Fetal Medicine has 2,300 square meters of experimental space, which consists of Maternal-Fetal Metabolism Research Laboratory, Intrauterine Programming and Epigenetic Research Laboratory, Embryonic Development and Organogenesis Research Laboratory, and Targeted Therapy Research Laboratory for Major Pregnancy Diseases. It is equipped with experimental equipments worth more than 45 million RMB, mainly including: triple quadrupole liquid chromatography-mass spectrometry (LC-MS/MS), two-photon microscope, small animal ultrasound system, flow cytometer, ultracentrifuge, real-time label-free cell recorder, and nanoparticle tracking analyzer.
Main Research Direction
After more than 30 years of development and precipitation, the laboratory has responded positively to the adjustment of international fertility policy and focused on the needs of people's livelihood, and has condensed and focused on four main research directions:
(1) Molecular Pathology of Major Pregnancy Diseases
(2) Fetal intrauterine programming and expression genetics.
(3) Screening and prevention of major birth defects
(4) Novel nanomedicine targeted therapy for major pregnancy diseases.
